|  | Cancer | Hodgkin Lymphoma

Hodgkin Lymphoma Treatment: Chemo, Radiation, Transplant, and Novel Therapies

Hodgkin lymphoma (HL) is a highly curable B-cell malignancy. Treatment is risk-adapted based on stage, prognostic factors (IPS), and patient factors.

Standard Frontline Regimens

Key Modalities

  • Chemotherapy: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) – backbone. Bleomycin lung toxicity (avoid >60, pulmonary dysfunction).
  • Radiation (ISRT): Involved-site RT; modern techniques (IMRT, proton) spare heart, breast, lung.
  • Autologous Stem Cell Transplant (ASCT): Standard for relapsed/refractory HL. High-dose BEAM → autologous rescue. 5-yr PFS ~50–60%.
  • Allogeneic Transplant: For post-ASCT relapse; graft-versus-lymphoma effect.

Novel / Targeted Therapies (Relapsed/Refractory)

  • Brentuximab vedotin (BV): Anti-CD30 ADC – single agent or + bendamustine, AVD.
  • PD-1 inhibitors (pembrolizumab, nivolumab): High RR in r/r HL; + BV synergistic.
  • CAR T-cell therapy: Emerging for multiply relapsed.

Survivorship

  • Late effects: secondary cancers (breast, lung, thyroid), cardiovascular disease, hypothyroidism, infertility, fatigue.
  • Risk-adapted follow-up: echocardiogram, breast MRI (if chest RT), thyroid function, lipid profile, vaccination.

>80% long-term cure for advanced stage; >90% for early stage. Multidisciplinary care essential.

Hodgkin Lymphoma - Related Articles

Health Sciences © https://www.222health.com

Stage / RiskPreferred RegimenKey Details
Early favorable (IA–IIA, no risk factors)ABVD × 2–4 cycles ± ISRT (20–30 Gy)De-escalation trials (RAPID, H10) omit radiation if PET-negative.
Early unfavorable (IA–IIA + risk factors)ABVD × 4–6 cycles + ISRT (30 Gy)Risk factors: bulky disease, >3 nodes, ESR>50, age>50.
Advanced (III–IV)ABVD × 6 cycles or escalated BEACOPP × 4–6 + ISRT to bulky sitesBEACOPP higher CR but more toxicity (infertility, AML); age<60.